<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01832220</url>
  </required_header>
  <id_info>
    <org_study_id>13010343</org_study_id>
    <secondary_id>U01HL112707</secondary_id>
    <nct_id>NCT01832220</nct_id>
  </id_info>
  <brief_title>Genomic Research in Alpha-1 Antitrypsin Deficiency</brief_title>
  <acronym>GRADS Alpha-1</acronym>
  <official_title>Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) - Alpha-1 Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project is designed to examine the interaction between the microflora in the lower
      airway and the concentration of a serum protein called alpha-1 antitrypsin. The hypothesis is
      that alpha-1 antitrypsin impacts the diversity and content of the lower airway microflora,
      resulting in a less inflammatory airway.

      The Specific Aims are:

        1. To compare the lower respiratory tract microbiome and virome population diversity and
           content in age and GOLD stage matched PiZZ individuals not receiving augmentation
           therapy, PiZZ individuals on augmentation therapy, PiMZ individuals not receiving
           augmentation therapy, and PiMM individuals with chronic obstructive pulmonary disease
           (COPD).

        2. Determine correlations between bronchoalveolar lavage (BAL) and peripheral blood gene
           expression patterns and patterns in lung microbial and viral populations across all
           cohorts.

        3. Correlate the presence or absence of computed tomography (CT) bronchiectasis and
           bronchiolectasis with patterns in the microbiome population diversity and content.

        4. To identify and define novel molecular phenotypes of Alpha-1 Antitrypsin Deficiency
           (AATD) based on computational integration of clinical, transcriptomic, and microbiome
           data.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Alpha-1 Antitrypsin Deficiency (AATD, Alpha-1) is a genetic condition that predisposes to
      early onset pulmonary emphysema and airways obstruction, often indistinguishable from usual
      smoker's chronic obstructive pulmonary disease (COPD). Prominent features of AATD COPD
      include basilar predominant panacinar emphysema, frequent radiographic bronchiectasis, and a
      prominent interaction with environmental factors that influence clinical disease phenotypes.

      Alpha-1 antitrypsin (AAT) is the most abundant serum and lung antiprotease and has a variety
      of biologic activities that influence lung homeostasis. Prominent among these are roles in
      neutrophil elastase inhibition, antiprotease activities against cathepsins, involvement in
      the complement cascade, and interaction with toll receptors.

      Since the effects of AAT on lung homeostasis remain poorly understood, the Alpha-1 protocol
      for the Genomic Research in AAT Deficiency and Sarcoidosis (GRADS) grant (hereafter called
      GRADS Alpha-1 protocol) is designed to investigate the overarching hypothesis that alpha-1
      antitrypsin (AAT) impacts the diversity and content of the lower airway microflora, resulting
      in a less inflammatory airway.

      Since the risk for bronchiectasis, COPD severity as measured by GOLD stage, and emphysema
      extent is proportional to the serum AAT concentration, comparison between different genotypes
      of AAT replete and deficient populations will provide data to determine if the diversity and
      content of the lower airway microflora influence the risk of COPD in the AATD population. The
      AATD population is selected because these individuals have a measurable interaction with
      environmental burdens22,28 and may be key to garnering an understanding of the interplay
      between this important anti-protease, airways and lower lung inflammation, peripheral blood
      gene expression, and radiologic and clinical phenotypes of COPD.

      The GRADS Alpha-1 Study is a prospective cross-sectional cohort study that will enroll
      approximately 200 participants at seven clinical centers with a total of nine recruitment
      locations over two years. An ancillary application to SPIROMICS will request data from 50
      PiMM subjects, all (estimate 10) PiMZ subjects, and any (estimate 1) PiZZ subjects. The
      remainder of the participants (N=~139) will be recruited through GRADS Alpha-1 centers. All
      participants will have two study-related visits (Baseline and Bronchoscopy). During the study
      visits, clinic staff will conduct physical examinations and tests, collect biological
      specimens, and administer a series of questionnaires to study participants. Participants
      could also receive a telephone call to determine the final status of any adverse event, 1
      month after study conclusion.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">September 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number and diversity of lower respiratory tract (LRT) microbes</measure>
    <time_frame>Single time point split into 2 visits over 1 month</time_frame>
    <description>Presenting characteristics (e.g., sex) will be compared among those with and without augmentation therapy using the appropriate test for continuous (e.g., t-test, Wilcoxon) or discrete (e.g., chi-square) data. Paired t-test will be used to compare the diversity, as measured by the number of microbes, and McNemar's test will be used to compare the lower respiratory tract (LRT) microbiome and virome, assessed by the presence or absence of specific organisms (e.g., viral, gram negative bacteria). Conditional logistic regression will be used to determine if there is an independent association with the use of augmentation therapy after controlling for presenting characteristics that differed between the two populations.
The primary analysis will determine if the PiZZ individuals on augmentation therapy have a difference in the number and diversity of LRT microbes identified than matched PiZZ individuals who are not on augmentation therapy.</description>
  </primary_outcome>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Actual">140</enrollment>
  <condition>Alpha 1 Antitrypsin Deficiency</condition>
  <condition>AATD</condition>
  <arm_group>
    <arm_group_label>PiZZ not on therapy</arm_group_label>
    <description>Individuals with the PiZZ genotype not on augmentation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PiZZ on therapy</arm_group_label>
    <description>Individuals with the PiZZ genotype on augmentation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PiMZ not on therapy</arm_group_label>
    <description>Individuals with the PiMZ genotype not on augmentation therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PiMM with COPD</arm_group_label>
    <description>Individuals with the PiMM genotype and COPD.</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, urine, stool, BAL fluid.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The GRADS Alpha-1 Study will enroll approximately 200 participants over two years. An
        ancillary application to SPIROMICS will request data from 50 PiMM subjects, all (estimate
        10) PiMZ subjects, and any (estimate 1) PiZZ subjects. The remainder of the participants
        (N=~150) will be recruited through nine GRADS clinical sites.

        Potential participants are invited to participate through the Alpha-1 Foundation Research
        Registry by email, telephone, mailings, or website per Registry protocols and procedures.
        Additionally, participants are recruited at the clinical centers by invitations to
        participate through flyers, websites and mailings and by physician referrals. Other
        recruitment protocols approved by the local institutional review board for human research
        are allowed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age between age 40 and 80 (inclusive) at Baseline Visit

          2. Alpha-1 Antitrypsin genotype PiZZ or PiMZ

          3. Able to tolerate and willing to undergo study procedures

          4. Signed informed consent

        Exclusion Criteria:

          1. History of comorbid condition severe enough to significantly increase risks based on
             investigator discretion

          2. Diagnosis of unstable cardiovascular disease including myocardial infarction in the
             past 6 weeks, uncontrolled congestive heart failure, or uncontrolled arrhythmia

          3. Partial pressure of oxygen in the blood (PaO2) on room air at rest &lt;50 mmHg or
             saturation level of oxygen in hemoglobin(SaO2) on room air at rest &lt;85%

          4. Post bronchodilator Forced Expiratory Volume in One Second (FEV1)&lt;30% predicted

          5. Use of anticoagulation (patients on warfarin or clopidogrel will be excluded; patients
             on aspirin alone can be studied even with concurrent use)

          6. Dementia or other cognitive dysfunction which in the opinion of the investigator would
             prevent the participant from consenting to the study or completing study procedures

          7. Active pulmonary infection with tuberculosis

          8. History of pulmonary embolism in the past 2 years

          9. Non-COPD obstructive disease (various bronchiolitides, sarcoid, LAM, histiocytosis X)
             or parenchymal lung disease, pulmonary vascular disease, pleural disease, severe
             kyphoscoliosis, neuromuscular weakness, or other cardiovascular and pulmonary disease,
             that, in the opinion of the investigator, limit the interpretability of the pulmonary
             function measures

         10. Prior significant difficulties with pulmonary function testing

         11. Hypersensitivity to or intolerance of albuterol sulfate or ipratropium bromide or
             propellants or excipients of the inhalers

         12. Hypersensitivity to or intolerance of all drugs required for sedation during conscious
             sedation bronchoscopy.

         13. History of Lung volume reduction surgery, lung resection or bronchoscopic lung volume
             reduction in any form

         14. History of lung or other organ transplant

         15. History of large thoracic metal implants (e.g., Automatic Implantable Cardioverter
             Defibrillators (AICD) and/or pacemaker) that in the opinion of the investigator limit
             the interpretability of CT scans

         16. Currently taking &gt;=10mg a day/20mg every other day of prednisone or equivalent
             systemic corticosteroid

         17. Currently taking any immunosuppressive agent excepting systemic corticosteroids

         18. History of lung cancer or any cancer that spread to multiple locations in the body

         19. Current illicit substance abuse, excluding marijuana

         20. Known HIV/AIDS infection

         21. History of or current exposure to chemotherapy or radiation treatments that, in the
             opinion of the investigator, limits the interpretability of the pulmonary function
             measures.

         22. Has a BMI &gt; 40 kg/m2 at baseline exam

         23. Current or planned pregnancy within the study course.

         24. Currently institutionalized (e.g., prisons, long-term care facilities)

         25. Have a genotype of PiMZ and ever received intravenous or inhaled alpha-1 augmentation
             therapy (Alpha-1 Proteinase Inhibitor, A1PI)

        Conditional Exclusions

          1. Participants who present with an upper respiratory infection or pulmonary
             exacerbation, either solely participant-identified or that has been clinically
             treated, in the last six weeks can be rescreened for the study once the six-week
             window has passed.

          2. Participants who present with current use of acute antibiotics or steroids can be
             rescreened for the study â‰¥30 days after discontinuing acute antibiotics/steroids. This
             does not apply to participants who are on chronic prednisone therapy of &lt;10 mg per day
             or &lt;20 mg every other day.

          3. Participants who present with a myocardial infarction or eye, chest, or abdominal
             surgery within six weeks can be rescreened after the six week window has passed. Study
             coordinators should consult with the site principal investigator prior to rescreening
             these participants.

          4. Female participants who present &lt;3 months after giving birth will be asked to
             reschedule their visit until three months have passed since the birth.

          5. Individuals who are PiZZ receiving alpha-1 augmentation therapy (Alpha-1 Proteinase
             Inhibitor, A1PI) must be off augmentation therapy for &gt;6 months to qualify for
             stratified enrollment in the PiZZ group not receiving augmentation therapy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Naftali Kaminski, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stephen Wisniewski, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Becich, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California - San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Jewish Health</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37240</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.gradslung.org/index.html</url>
    <description>Study Website</description>
  </link>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 10, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 16, 2013</study_first_posted>
  <last_update_submitted>January 11, 2016</last_update_submitted>
  <last_update_submitted_qc>January 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yale University</investigator_affiliation>
    <investigator_full_name>Naftali Kaminski</investigator_full_name>
    <investigator_title>Boehringer-Ingelheim Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine</investigator_title>
  </responsible_party>
  <keyword>Genomics</keyword>
  <keyword>Microbiome</keyword>
  <keyword>Microflora</keyword>
  <keyword>Virome</keyword>
  <keyword>Alpha-1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alpha 1-Antitrypsin</mesh_term>
    <mesh_term>Protein C Inhibitor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

